Compare Abeona Therapeutics Inc (ABEO) vs Dicks Sporting Goods Inc (DKS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Dicks Sporting Goods Inc — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Dicks Sporting Goods Inc trades at $215.83 (market cap $19.97B). The key difference: Dicks Sporting Goods Inc is far larger — about 53.5× Abeona Therapeutics Inc's market cap, and Dicks Sporting Goods Inc pays a 2.24% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | DKS | |
|---|---|---|
Market Cap | $373.32M | $19.97B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $239.17 |
52-Week Low | $4.17 | $187.78 |
Enterprise Value | $228.22M | $26.76B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Dick's Sporting Goods (DKS) trades at $229.02, down 3.03% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals with consistent earnings beats, a P/E of 22.3, and a net income margin of 4.71%. Recent developments include the launch of ScoreCard+ loyalty program and partnerships with Lids, enhancing growth prospects amid positive analyst sentiment.
The outlook for DKS is positive, supported by robust earnings performance and strategic initiatives. Risks include potential fiduciary concerns highlighted in recent legal investigations and competitive pressures. With a consensus price target of $261, representing a 14% upside, the stock presents a compelling opportunity, though investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →
